Self Regional Healthcare

Self Regional Healthcare
1325 Spring Street
Greenwood, SC 29646
864-725-4111

National Cancer Institute Community Oncology Research Program logo

As an affiliate of the Medical University of South Carolina, Self Regional Healthcare is an active Minority/Underserved NCORP site. Self Regional Healthcare is currently active on the following clinical trials addressing various cancer types. Ask your health care provider for more information.

All Disease Sites

  • NCICOVID: NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
    Trial Details

Breast

  • A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
    Trial Details
  • A011401: Breast Cancer WEight Loss Study (BWEL Study)
    Trial Details
  • A011502: Aspirin for Breast Cancer Study (ABC study)
    Trial Details
  • BR003: Testing the addition of carboplatin to usual chemotherapy in high-risk triple-negative breast cancer
    Trial Details
  • CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer - PENDING
    Trial Details
  • EA1183: FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE Study - PENDING
    Trial Details
  • EAZ171: Testing if docetaxel or paclitaxel induces less peripheral neuropathy in African American women
    Trial Details
  • S1418/BR006: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
    Trial Details
  • WF-97116: Donepezil for Cognitive Impairment (REMEMBER)
    Trial Details

Gastrointestinal

  • A021703: Testing the addition of high-dose vitamin D3 to usual chemotherapy treatment and bevacizumab for untreated advanced colorectal cancer
    Trial Details
  • A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
    Trial Details
  • GI005: Using cancer cells in the blood (ctDNA) to predict if chemotherapy will benefit patients who have had surgery for early stage colon cancer
    Trial Details
  • WF-1806: Low Muscle Mass and its Role in Side Effects from Chemotherapy in Older Adults with Colorectal Cancer
    Trial Details

Genitourinary

  • A031501: Testing MK-3475 (pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer
    Trial Details
  • GU005: Testing short course of radiation therapy versus usual radiation therapy for prostate cancer
    Trial Details

Malignant Hematology

  • A051701: Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
    Trial Details
  • EAA173: Testing the Addition of Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Multiple Myeloma
    Trial Details
  • EA9161: Assessing the Ability of Combination Treatment with Venetoclax to Permit Time Limited Therapy in CLL
    Trial Details
  • NHLBI-MDS: Protocol for the collection of information and samples to be used in the study of MDS
    Trial Details

Neuro-Oncology

  • CCTG CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) plus Memantine for 5-15 Brain Metastases
    Trial Details

Thoracic/Lung

  • A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
    Trial Details
  • A081105: Testing whether or not a drug that is known to “target” a certain kind of lung tumor works in patients with that type of tumor (ALCHEMIST Substudy)
    Trial Details
  • CC003: Testing whether avoiding the hippocampus during whole-brain radiation therapy prevents cognitive side effects in patients with small cell lung cancer
    Trial Details
  • E4512: Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer (ALCHEMIST Substudy)
    Trial Details
  • EA5163/S1709 INSIGNA: Testing the timing of immunotherapy alone or with chemotherapy as first line treatment and maintenance in non-small cell lung cancer
    Trial Details
  • EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC - PENDING
    Trial Details
  • LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial - PENDING
    Trial Details
  • S1827: Testing whether the use of brain scans alone instead of brain scans plus preventive brain radiation affects lifespan in patients with small cell lung cancer
    Trial Details